Publications by authors named "Gul Sema Yildiran Keskin"
Objective: We aimed to investigate response rates, survival analyses and factors affecting survival in patients with relapsed or refractory ovarian germ cell tumours who had previously received multiple lines of treatment, including high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).
Methods: This study was designed as a cross-sectional, retrospective study.
Results: Twenty-one patients were included.
Introduction: The optimal management of relapsed/refractory germ cell tumors remains unsettled. In this study, we aimed to evaluate the efficacy of high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) as salvage therapy in patients who progressed after at least one line of cisplatin-based chemotherapy.
Methods: We retrospectively reported the results of 133 patients who underwent HDCT and ASCT as salvage therapy from 2016 to 2021.
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study.
J Chemother
March 2024
Article Synopsis
- The MONALEESA-7 study is the only phase 3 research on CDK 4-6 inhibitors for premenopausal patients with hormone receptor-positive, HER2 negative metastatic breast cancer, but there is limited data on palbociclib's effectiveness.
- Our multicenter, retrospective study included 319 patients to evaluate the effectiveness of palbociclib and ribociclib in first-line treatment and how dose reduction due to neutropenia affects progression-free survival (PFS).
- Results showed similar median PFS for both drugs (26.83 months for palbociclib and 29.86 months for ribociclib) and no significant impact of dose reduction on effectiveness, with P
Objective: Cancers have been reported to worsen the clinical course of coronavirus disease 2019 (COVID-19) infection. We aimed to demonstrate the real-life data on health outcomes in COVID-19-infected cancer patients.
Materials And Methods: We analyzed the data of 43 COVID-19-infected cancer patients in our COVID-19 clinics between March 25, 2020, and May 9, 2020, retrospectively.